ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Diet/Growth Factor Mechanisms of Gut Adaptation

This study has been completed.

Sponsored by: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
ClinicalTrials.gov Identifier: NCT00067860
  Purpose

This is a double-blind randomized controlled study on the clinical and metabolic effects and underlying gut mucosal mechanisms of modified diet, with or without recombinant human growth hormone, in adults with severe short bowel syndrome dependent upon parenteral nutrition. Clinical endpoints include ability to wean patients from parenteral feeding, metabolic endpoints include gut nutrient absorptive function and molecular endpoints include expression of growth factors and nutrient transporters in small bowel and colonic mucosa. The 6-month study is performed, in part, in the General Clinical Research Center for inpatient stays and outpatient visits.


Condition Intervention Phase
Short Bowel Syndrome
Drug: recombinant human growth hormone
Behavioral: diet modification
Phase II

ChemIDplus related topics:   Somatotropin    Somatropin   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Official Title:   Diet/Growth Factor Mechanisms of Gut Adaptation

Further study details as provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):

Estimated Enrollment:   30
Study Start Date:   October 1996
Study Completion Date:   December 2006
Primary Completion Date:   December 2006 (Final data collection date for primary outcome measure)

Detailed Description:

This is a double-blind randomized controlled study on the clinical and metabolic effects and underlying gut mucosal mechanisms of modified diet, with or without recombinant human growth hormone, in adults with severe short bowel syndrome dependent upon parenteral nutrition. Clinical endpoints include ability to wean patients from parenteral feeding, metabolic endpoints include gut nutrient absorptive function and molecular endpoints include expression of growth factors and nutrient transporters in small bowel and colonic mucosa. The 6-month study is performed, in part, in the General Clinical Research Center for inpatient stays and outpatient visits.

  Eligibility
Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria
  • Parenteral nutrition-dependent adults with short gut syndrome.
  • Patients must not have diabetes mellitus or active malignancy within the past 5 years.
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00067860

Locations
United States, Georgia
Emory University School of Medicine    
      Atlanta, Georgia, United States, 30322

Sponsors and Collaborators

Investigators
Principal Investigator:     Thomas R Ziegler, MD     Emory University    
  More Information


Study ID Numbers:   DGFMGA DK55850, DK55850
First Received:   August 29, 2003
Last Updated:   January 8, 2008
ClinicalTrials.gov Identifier:   NCT00067860
Health Authority:   United States: Food and Drug Administration

Study placed in the following topic categories:
Digestive System Diseases
Postoperative Complications
Gastrointestinal Diseases
Malabsorption Syndromes
Short Bowel Syndrome
Intestinal Diseases

Additional relevant MeSH terms:
Disease
Pathologic Processes
Syndrome

ClinicalTrials.gov processed this record on October 07, 2008




Links to all studies - primarily for crawlers